Skip to main content
Triangle logo TriangleGet started

Avelumab (NCT05327686)

Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial: a one-minute explainerNCT053276861 min

Avelumab trial for Metastatic Renal Cell Carcinoma (NCT05327686). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with unresected kidney cancer, intermediate or poor risk, and unresectable involved lymph nodes or distant spread. Immediate kidney removal must be unsuitable or declined.

The idea: add precise radiation to the kidney tumor while using an immune-based drug combination. Radiation damages tumor cells; the drugs activate immune attack, sometimes also blocking blood-vessel growth. Randomized patients receive drug treatment alone or with three radiation sessions over one to three weeks.

This phase 2 study plans 240 patients. William Hall leads the NRG Oncology study, with 303 recruiting US sites.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.